GSK lawyer: CMA paroxetine decision was “overreach”
The UK’s antitrust watchdog was wrong to paint patent settlements between GlaxoSmithKline and two generic drugmakers as an illegal pay-for-delay scheme, counsel to the pharmaceutical company told the Competition Appeal Tribunal today.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.